Andere talen Pulse Biosciences, Inc.

Aandelen

PLSE

US74587B1017

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 17-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
7,47 ^USD	-3,98%		+0,81%	-38,97%

01/04	Sectorupdate: Gezondheidszorgaandelen dalen laat in de middag	MT
01/04	Aandelen Pulse Biosciences dalen na Q4-resultaten, plannen voor claimemissie	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Sector Update: Health Care Stocks Slide Late Afternoon	01/04
Pulse Biosciences Shares Fall After Q4 Results, Rights Issue Plans	01/04
Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2023 Financial Results	28/03
Pulse Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
Pulse Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	28/03
Pulse Biosciences Announces Plans to Initiate a Rights Offering	28/03
Pulse Biosciences Schedules Fourth Quarter & Full Year 2023 Financial Results Conference Call for March 28, 2024	14/03
Sector Update: Health Care Stocks Ease Late Afternoon	08/03
Pulse Biosciences Gets FDA Clearance For Percutaneous Electrode System	08/03
Pulse Biosciences Announces FDA 510(k) Clearance for its CellFX® nsPFA™ Percutaneous Electrode System	08/03
Pulse Biosciences, Inc. Announces FDA 510(K) Clearance for its CellFX nsPFA Percutaneous Electrode System	08/03
PULSE BIOSCIENCES ANNOUNCES POSITIVE 60-DAY FOLLOW-UP EVALUATIONS FOR INITIAL PATIENTS TREATED IN THE CELLFX NSPFA 360-degree CARDIAC CATHETER FIRST-IN-HUMAN FEASIBILITY STUDY	15/02
Pulse Biosciences, Inc. Announces Positive 60-Day Follow-Up Evaluations for Initial Patients Treated in the Cellfx Nspfa 360° Cardiac Catheter First-In-Human Feasibility Study	14/02
Pulse Biosciences Announces Positive 60-Day Follow-Up Evaluations for Initial Patients treated in the CellFX® nsPFA™ 360° Cardiac Catheter First-in-Human Feasibility Study	14/02
Pulse Biosciences Announces Preliminary Findings from its CellFX nsPFA 360 Cardiac Catheter First-In-Human Feasibility Study to be Featured in Podium Presentation at the AF Symposium	31/01
Sector Update: Health Care Stocks Decline Pre-Bell Tuesday	02/01
Pulse Biosciences Files FDA Notification to Advance Testing of New Cardiac Clamp	02/01
Pulse Biosciences Files 510(K) Submission with U.S. FDA for its CellFX nsPFA Cardiac Clamp	02/01
Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX® nsPFA™ Cardiac Clamp	02/01
Pulse Biosciences Announces First-in-Human Procedures with its Novel CellFX™ Nanosecond Pulsed Field Ablation (nsPFA™) Cardiac Catheter	20/12

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Pulse Biosciences, Inc.

Aandelen

PLSE

US74587B1017

Andere talen

Filters